A Phase 2/3 interventional study of Vortioxetine and Placebo in Depressive Disorder, Major, sponsored by Takeda. Completed at 73 sites in 16 countries. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2013-12-18.
Sponsored by Takeda · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 14th largest by enrollment, is one of 6 that started in 2010, is one of 2 in phase 2/3, and was the 16th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 20 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 33 · Phase 4 13
First in 2006; this study’s year is marked. 6 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 600 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 413 across the 54 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 54 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
26 studies in Depressive Disorder, Major by Takeda: 1 open now, 1 under way, 1 of them phase 3. Of 25 finished, 24 (96%) have results posted.
Among the 26 studies in Depressive Disorder, Major by Takeda, this one is the 11th largest by enrollment of the 24 interventional ones that give a count, is one of 5 that started in 2010, is the only one in phase 2/3, and was the 11th registered.
Takeda’s Depressive Disorder, Major studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of multiple doses of vortioxetine, once daily (QD), in participants with major depressive disorder.
The drug that was tested in this study is called vortioxetine. Vortioxetine is being tested to treat depression in adults who have major depressive disorder (MDD). This study looked at MDD relief in people who took varying doses of vortioxetine.
The study enrolled 600 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the four treatment groups-which remained undisclosed to the patient and study doctor during the study (unless there was an urgent medical need):
All participants were asked to take one capsule at the same time each day throughout the study.
This multi-center trial was conducted in 14 countries in Europe and Asia. The overall time to participate in this study was up to 13 weeks. Participants made weekly visits to the clinic during the first 2 weeks of the 8-week treatment period and then every 2 weeks up to the end of the 8-week treatment period. Participants who completed the 8-week treatment period entered a 2-week discontinuation period to assess potential discontinuation symptoms 1 and 2 weeks after the end of the 8-week treatment period. A safety follow-up contact (visit or phone call) was made 4 weeks after completion of the 8-week double-blind treatment period (2 weeks after the end of the 2-week discontinuation period).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has one or more of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vortioxetine placebo-matching tablets, orally, once daily for up to 10 weeks.
Drug: Placebo
Vortioxetine 5 mg, tablets, orally, once daily for 8 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily for 2 weeks.
Drug: Vortioxetine · Drug: Placebo
Vortioxetine 10 mg, tablets, orally, once daily for 8 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily for 2 weeks.
Drug: Vortioxetine · Drug: Placebo
Vortioxetine 10 mg, tablets, orally, once daily for 1 week, followed by vortioxetine 20 mg, tablets, orally, once daily for 7 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily, for 2 weeks.
Drug: Vortioxetine · Drug: Placebo
Vortioxetine tablets
Also known as: Lu AA21004, Brintellix®
Vortioxetine placebo-matching tablets
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
The MADRS is a depression rating scale consisting of 10 items, each rated 0 (normal) to 6 (most abnormal). The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. Least squares (LS) means were from an Analysis of Covariance (ANCOVA) model with treatment as a fixed factor and the Baseline value as a covariate.
Time frame: Baseline and Week 8
Percentage of Participants With a MADRS Response at Week 8
Response is defined as a participant with a ≥50% decrease in Montgomery Åsberg Depression Rating Scale (MADRS) total score from Baseline. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.
Time frame: Baseline and Week 8
Percentage of Participants in MADRS Remission at Week 8
Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.
Time frame: Week 8
Mean Clinical Global Impression Scale - Improvement (CGI-I) Score at Week 8
The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from an ANCOVA model with treatment as a fixed factor and the Baseline Clinical Global Impression-Severity of Illness (CGI-S) score as a covariate.
Time frame: Week 8
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8
The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and family life or home responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from an ANCOVA model with treatment as a fixed factor and the Baseline value as a covariate.
Time frame: Baseline and Week 8
Participants took part in the study at 90 investigative sites in Japan, Europe and Asia/Oceania from 18 November 2010 to 25 April 2012.
| Milestone | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|---|
| Started | 152 | 144 | 150 | 154 |
| Treated | 152 | 144 | 148 | 150 |
| Completed | 136 | 127 | 132 | 132 |
| Not completed | 16 | 17 | 18 | 22 |
| Withdrew: Pretreatment event or adverse event (ae) | 6 | 2 | 9 | 9 |
| Withdrew: Major protocol deviation | 1 | 1 | 0 | 4 |
| Withdrew: Lost to follow-up | 1 | 2 | 4 | 2 |
| Withdrew: Withdrawal of consent | 3 | 9 | 3 | 4 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 2 | 2 | 2 | 2 |
| Withdrew: Noncompliance with study drug | 3 | 1 | 0 | 0 |
The MADRS is a depression rating scale consisting of 10 items, each rated 0 (normal) to 6 (most abnormal). The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. Least squares (LS) means were from an Analysis of Covariance (ANCOVA) model with treatment as a fixed factor and the Baseline value as a covariate.
| scores on a scale | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|---|
| Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | -13.99 ± 0.783 | -14.61 ± 0.805 | -15.68 ± 0.791 | -15.82 ± 0.786 |
Response is defined as a participant with a ≥50% decrease in Montgomery Åsberg Depression Rating Scale (MADRS) total score from Baseline. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.
| percentage of participants | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|---|
| Percentage of Participants With a MADRS Response at Week 8 | 39.3 | 49.3 | 54.4 | 51.0 |
Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.
| percentage of participants | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|---|
| Percentage of Participants in MADRS Remission at Week 8 | 26.7 | 24.6 | 29.3 | 30.9 |
The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from an ANCOVA model with treatment as a fixed factor and the Baseline Clinical Global Impression-Severity of Illness (CGI-S) score as a covariate.
| scores on a scale | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|---|
| Mean Clinical Global Impression Scale - Improvement (CGI-I) Score at Week 8 | 2.54 ± 0.087 | 2.37 ± 0.089 | 2.27 ± 0.088 | 2.36 ± 0.087 |
The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and family life or home responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from an ANCOVA model with treatment as a fixed factor and the Baseline value as a covariate.
| scores on a scale | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|---|
| Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8 | -6.20 ± 0.602 | -6.38 ± 0.647 | -7.97 ± 0.633 | -7.26 ± 0.622 |
Collected over A treatment-emergent adverse event is defined as any AE whose onset occurs or intensity increases after the first dose of double-blind study medication through 2 weeks after the last dose of double-blind study medication.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/151 (0.7%) | 97/151 (64.2%) |
| Vortioxetine 5 mg | — | 2/144 (1.4%) | 96/144 (66.7%) |
| Vortioxetine 10 mg | — | 2/148 (1.4%) | 93/148 (62.8%) |
| Vortioxetine 20 mg | — | 3/150 (2%) | 106/150 (70.7%) |
| Event | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|---|
| SyncopeNervous system disorders | 0/151 | 1/144 | 0/148 | 0/150 |
| Renal colicRenal and urinary disorders | 0/151 | 1/144 | 0/148 | 0/150 |
| GastroenteritisInfections and infestations | 0/151 | 0/144 | 1/148 | 0/150 |
| DepressionPsychiatric disorders | 0/151 | 0/144 | 1/148 | 0/150 |
| PyelonephritisInfections and infestations | 0/151 | 0/144 | 0/148 | 1/150 |
| Abortion missedPregnancy, puerperium and perinatal conditions | 0/151 | 0/144 | 0/148 | 1/150 |
| Suicide attemptPsychiatric disorders | 1/151 | 0/144 | 0/148 | 1/150 |
| Suicidal ideationPsychiatric disorders | 0/151 | 0/144 | 0/148 | 1/150 |
| Event | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 11/151 | 26/144 | 27/148 | 37/150 |
| NasopharyngitisInfections and infestations | 18/151 | 24/144 | 18/148 | 21/150 |
| HeadacheNervous system disorders | 21/151 | 16/144 | 19/148 | 23/150 |
| DiarrhoeaGastrointestinal disorders | 14/151 | 7/144 | 6/148 | 5/150 |
| DizzinessNervous system disorders | 5/151 | 7/144 | 8/148 | 10/150 |
| Dry mouthGastrointestinal disorders | 3/151 | 3/144 | 6/148 | 9/150 |
| InsomniaPsychiatric disorders | 2/151 | 4/144 | 4/148 | 9/150 |
| ConstipationGastrointestinal disorders | 3/151 | 6/144 | 5/148 | 8/150 |
| SomnolenceNervous system disorders | 2/151 | 7/144 | 7/148 | 6/150 |
| FatigueGeneral disorders | 2/151 | 6/144 | 4/148 | 5/150 |
| Age Continuous(years) | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|---|
| Mean | 43.6 ± 11.57 | 44.2 ± 11.89 | 45.7 ± 10.90 | 44.0 ± 11.79 | 44.4 ± 11.54 |
| Sex: Female, Male(Participants) | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|---|
| Female | 91 | 98 | 93 | 93 | 375 |
| Male | 61 | 46 | 57 | 61 | 225 |
| Race/Ethnicity, Customized(participants) | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|---|
| Caucasian (or White, including Hispanic) | 104 | 101 | 104 | 105 | 414 |
| Asian | 48 | 43 | 46 | 49 | 186 |
| Region of Enrollment(participants) | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|---|
| Croatia | 0 | 1 | 0 | 2 | 3 |
| Finland | 5 | 5 | 5 | 5 | 20 |
| Germany | 50 | 50 | 50 | 49 | 199 |
| India | 3 | 3 | 3 | 2 | 11 |
| Japan | 33 | 32 | 31 | 33 | 129 |
| Latvia | 3 | 2 | 2 | 3 | 10 |
| Malaysia | 2 | 0 | 0 | 2 | 4 |
| Philippines | 4 | 2 | 4 | 3 | 13 |
| Poland | 20 | 18 | 20 | 21 | 79 |
| Romania | 5 | 4 | 6 | 3 | 18 |
| Russia | 13 | 13 | 12 | 13 | 51 |
| Serbia | 2 | 2 | 3 | 2 | 9 |
| South Korea | 6 | 6 | 7 | 8 | 27 |
| Ukraine | 6 | 6 | 7 | 8 | 27 |
| Height(cm) | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|---|
| Mean | 167.1 ± 8.75 | 167.2 ± 9.64 | 167.5 ± 9.40 | 167.5 ± 9.61 | 167.3 ± 9.33 |
| Weight(kg) | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|---|
| Mean | 69.70 ± 16.901 | 70.57 ± 18.214 | 73.37 ± 19.014 | 70.21 ± 18.189 | 70.95 ± 18.095 |
| Body Mass Index (BMI)(kg/m^2) | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|---|
| Mean | 24.82 ± 5.129 | 25.06 ± 5.432 | 25.93 ± 5.462 | 24.82 ± 5.206 | 25.15 ± 5.313 |
| Smoking Classification(participants) | Placebo | Vortioxetine 5 mg | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|---|
| Current smoker | 51 | 50 | 50 | 56 | 207 |
| Ex-smoker | 22 | 19 | 21 | 11 | 73 |
| Never smoked | 79 | 75 | 79 | 87 | 320 |
7 further baseline measures are reported on the registry.
The record gives a start of Nov 2010, a primary completion of Mar 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine